Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

Main Article Content

Andrew Blauvelt
Phoebe Rich
Howard Sofen
Jo Lambert
Joe Merola
Mark Lebwohl
Lauren Hippeli
Renata Kisa
Subhashis Banerjee
Alexa Kimball


psoriasis, scalp, nail, palmoplantar




1. Burke JR, et al. Sci Transl Med. 2019;11:1-16.

2. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

3. Armstrong A, et al.
Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25, 2021.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>